Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
News about Teva Pharmaceutical Industries Limited (TEVA) focuses on its transformation into an innovative biopharmaceutical company, its generics and biosimilars franchise, and developments across neuroscience and immunology. Company announcements highlight progress on its Pivot to Growth strategy, including updates on branded medicines such as AUSTEDO, AJOVY and UZEDY, as well as late-stage pipeline assets.
Recent news includes clinical and regulatory milestones for AJOVY (fremanezumab-vfrm), where Phase 3 SPACE trial results in children and adolescents with episodic migraine were published in the New England Journal of Medicine. These data supported U.S. FDA approval for preventive treatment of episodic migraine in pediatric patients who meet specified criteria, adding to AJOVY’s existing indication in adults. News items provide details on trial design, efficacy outcomes, and safety profile.
Investors and followers of TEVA can also find updates on pipeline programs such as olanzapine extended-release injectable suspension (TEV-'749) for schizophrenia and the anti‑IL‑15 antibody TEV-'408 for vitiligo and celiac disease, including regulatory submissions and funding agreements. Teva’s news flow covers biosimilar approvals and collaborations, such as European Commission approvals for denosumab biosimilars PONLIMSI and DEGEVMA and the U.S. settlement and license agreement for AVT06, a proposed biosimilar to Eylea.
In addition, TEVA news features financial and capital markets events, including rating agency actions, amendments to credit facilities, quarterly earnings release dates, conference call schedules, and participation in major healthcare conferences. This mix of clinical, regulatory, strategic and financial updates makes the TEVA news page a central resource for tracking how Teva’s generics base, innovative pipeline and biosimilars portfolio contribute to its stated Pivot to Growth strategy. Users interested in TEVA stock can monitor this page for ongoing disclosures that may inform their understanding of the company’s operations and strategic direction.
Teva Pharmaceutical Industries Ltd. reported Q4 and FY 2020 results, with Q4 revenues at $4.5 billion and FY 2020 revenues at $16.7 billion. Key highlights include non-GAAP EPS of $0.68 for Q4 and $2.57 for FY 2020. The company anticipates 2021 revenue between $16.4 billion and $16.8 billion, with non-GAAP EPS projected between $2.50 and $2.70. Despite experiencing a 1% revenue decline from 2019, gross profit increased by 3%, attributed to higher sales from AUSTEDO and AJOVY. Teva also reported cash flow from operations of $1.216 billion in 2020.
Teva Pharmaceuticals USA has launched a generic version of NuvaRing (etonogestrel and ethinyl estradiol vaginal ring) in the U.S. This AB-rated and bioequivalent contraceptive is now part of Teva’s extensive generic portfolio, enhancing access to women's health options. Teva currently offers over 550 FDA-approved generic medicines and leads in first-to-file opportunities with more than 100 pending in the U.S. The annual sales for etonogestrel and ethinyl estradiol products exceed $837 million, highlighting the market potential for this generic launch.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will announce its fourth quarter and full year 2020 financial results on February 10, 2021, at 7:00 a.m. ET. Following the release, a conference call will occur at 8:00 a.m. ET, with access numbers provided for participants. The call can also be streamed live via Teva's website. The company emphasizes its century-long commitment to medicine development, with over 3,500 products and a vast supply chain serving about 200 million people globally.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has announced that President & CEO Kåre Schultz will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 8:20 A.M. Eastern Time. Investors can access the live webcast via Teva’s Investor Relations website. An archived version will be available one hour post-session. Teva is a global leader in generic and specialty medicines, with over 3,500 products. Approximately 200 million people rely on Teva medicines daily, supported by a complex supply chain.
Teva Pharmaceuticals and MedinCell announced positive results from the RISE study, a Phase 3 trial of TV-46000/mdc-IRM, an extended-release injectable for schizophrenia. Patients receiving the treatment experienced a statistically significant delay in relapse compared to placebo, with reductions of 80.0% and 62.5% for monthly and bi-monthly doses, respectively (p<0.0001). No new safety concerns arose. Teva plans to continue leading development and regulatory processes for commercialization, while MedinCell will receive milestones and royalties.
Teva Respiratory, LLC is collaborating with Amazon Web Services (AWS) and Onica to create a cloud-based Digital Health Platform. This platform will support the FDA-approved Digihaler® inhalers, which feature built-in sensors and Bluetooth technology to track inhaler usage. The system aims to enhance patient-care provider communication and optimize treatment decisions. The platform's cloud hosting will provide scalability and security, facilitating easy access to inhaler event data for patients and healthcare providers. The Digihaler portfolio is now commercially available with FDA approval.
Teva Pharmaceutical Industries Ltd. announced results from a post hoc analysis of a long-term study on AJOVY® (fremanezumab-vfrm) for chronic and episodic migraine treatment. The analysis involved 1,043 patients, comparing migraine days during different dosing regimens. Findings showed no significant variation in migraine days between initial and final weeks of dosing. The mean weekly migraine days were 4.0 for chronic migraine and 2.3 for episodic migraine at baseline. No new safety signals were identified, and AJOVY remains the only long-acting anti-CGRP injection approved for both quarterly and monthly dosing.
Teva Pharmaceuticals USA has launched the FDA-approved generic versions of TRUVADA® and ATRIPLA® tablets, marking a significant step in increasing access to HIV treatments. These generics complement Teva's portfolio of over 10 HIV-related medications on the WHO's Essential Medicines list. The new generics provide vital options for the 1.2 million individuals living with HIV-1 in the U.S., as well as addressing the global shortfall of 12.6 million people without access to treatment. The wholesale acquisition cost is set at $48.51 per tablet for Emtricitabine/Tenofovir and $78.86 for the combination tablet.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will release its third quarter financial results on November 5, 2020, at 7:00 a.m. ET. A conference call and live webcast will follow at 8:00 a.m. ET. Participants can join by dialing specified numbers, with a passcode of 7275239. A replay will be available within 24 hours. Teva is a global leader in generic and specialty medicines with over 3,500 products, servicing around 200 million daily users worldwide. The company emphasizes that this release may include forward-looking statements subject to risks and uncertainties.